Pursuant to Second proviso to Regulation 30(6) and Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 we hereby inform you that the Board of Directors ....
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Shree Ganesh Biotech (India) Ltd's board, at its meeting on January 29, 2026, approved the unaudited standalone financial results for Q3 FY26 (quarter ended Dec 31, 2025) and the nine months ended Dec 31, 2025. Revenue from operations collapsed to ₹69.81 lakh in Q3 FY26 from ₹1,441.18 lakh in Q3 FY25 — a roughly 95% year-on-year drop. Nine-month revenue fell to ₹284.92 lakh from ₹1,995.18 lakh, an approximately 86% decline. Despite the sharp revenue contraction, Q3 profit after tax was ₹32.23 lakh (vs ₹77.17 lakh in Q3 FY25) and nine-month PAT was ₹66.34 lakh (vs ₹133.29 lakh), with margins appearing to expand because costs were cut sharply. The statutory auditor, Bipin & Co., issued an unqualified (clean) limited review report. Previous period figures have been restated/regrouped where necessary to make them comparable.
The dramatic ~95% crash in Q3 revenue is a serious red flag suggesting the core business has shrunk to a small fraction of its prior size — shareholders should treat this with caution as it points to major operational headwinds or loss of business. The clean auditor review is a minor positive, but it does not offset the steep top-line decline.